Steroids and Injury to the Developing Brain: Net Harm or Net Benefit?

Clinics in Perinatology

Volumn 41, Issue 1, 2014, Pages 191-208

  Malaeb, Shadi N ^a   Stonestreet, Barbara S ^b  

^a ST CHRISTOPHER'S HOSPITAL FOR CHILDREN   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Brain injury; Cerebral palsy; Controversy; Development; Glucocorticoids; Infant; Outcomes; Premature infant

Indexed keywords

BRAIN INJURY; CEREBRAL PALSY; CONTROVERSY; DEVELOPMENT; GLUCOCORTICOIDS; INFANT; OUTCOMES; PREMATURE INFANT;

BRAIN; BRONCHOPULMONARY DYSPLASIA; FEMALE; GLUCOCORTICOIDS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; NEUROPROTECTIVE AGENTS; PREGNANCY; TIME FACTORS;

EID: 84893812681     PISSN: 00955108     EISSN: 15579840     Source Type: Journal    
DOI: 10.1016/j.clp.2013.09.006     Document Type: Review

References (106)

1. Halliday H.L., Ehrenkranz R.A., Doyle L.W. Early (8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2010, (1). CD001146.
2. Halliday H.L., Ehrenkranz R.A., Doyle L.W. Late (>7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 2009, (1). CD001145.
3. Rice D., Barone S. Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models. Environ Health Perspect 2000, 108(Suppl 3):511-533.
4. Miles D.K., Kernie S.G. Activation of neural stem and progenitor cells after brain injury. Prog Brain Res 2006, 157:187-197.
5. Herrup K., Neve R., Ackerman S.L., et al. Divide and die: cell cycle events as triggers of nerve cell death. J Neurosci 2004, 24(42):9232-9239.
6. Malaeb S.N., Cohen S.S., Virgintino D., et al. Core concepts: development of the blood-brain barrier. Neo Reviews 2012, 13(4):e241-e250.
7. Abbott N.J., Friedman A. Overview and introduction: the blood-brain barrier in health and disease. Epilepsia 2012, 53(Suppl 6):1-6.
8. Spanswick S.C., Epp J.R., Sutherland R.J. Time-course of hippocampal granule cell degeneration and changes in adult neurogenesis after adrenalectomy in rats. Neuroscience 2011, 190:166-176.
9. Gould E., Woolley C.S., McEwen B.S. Short-term glucocorticoid manipulations affect neuronal morphology and survival in the adult dentate gyrus. Neuroscience 1990, 37(2):367-375.
10. Rugerio-Vargas C., Ramirez-Escoto M., DelaRosa-Rugerio C., et al. Prenatal corticosterone influences the trajectory of neuronal development, delaying or accelerating aspects of the Purkinje cell differentiation. Histol Histopathol 2007, 22(9):963-969.
11. Dunn M.E., Schilling K., Mugnaini E. Development and fine structure of murine Purkinje cells in dissociated cerebellar cultures: dendritic differentiation, synaptic maturation, and formation of cell-class specific features. Anat Embryol (Berl) 1998, 197(1):31-50.
12. Fuentes-Pardo B., Hernandez-Falcon J., Velazquez P.N., et al. Role of corticosterone on the development of passive electrical properties of cultured chick embryo neurons. J Dev Physiol 1990, 13(2):67-73.
13. Numakawa T., Kumamaru E., Adachi N., et al. Glucocorticoid receptor interaction with TrkB promotes BDNF-triggered PLC-gamma signaling for glutamate release via a glutamate transporter. Proc Natl Acad Sci U S A 2009, 106(2):647-652.
14. Jeanneteau F., Garabedian M.J., Chao M.V. Activation of Trk neurotrophin receptors by glucocorticoids provides a neuroprotective effect. Proc Natl Acad Sci U S A 2008, 105(12):4862-4867.
15. Bonett R.M., Hu F., Bagamasbad P., et al. Stressor and glucocorticoid-dependent induction of the immediate early gene kruppel-like factor 9: implications for neural development and plasticity. Endocrinology 2009, 150(4):1757-1765.
16. Liston C., Gan W.B. Glucocorticoids are critical regulators of dendritic spine development and plasticity in vivo. Proc Natl Acad Sci U S A 2011, 108(38):16074-16079.
17. Gray J.D., Milner T.A., McEwen B.S. Dynamic plasticity: the role of glucocorticoids, brain-derived neurotrophic factor and other trophic factors. Neuroscience 2013, 239:214-227.
18. Joubert L., Foucault I., Sagot Y., et al. Chemical inducers and transcriptional markers of oligodendrocyte differentiation. J Neurosci Res 2010, 88(12):2546-2557.
19. Campagnoni A.T., Verdi J.M., Verity A.N., et al. Posttranscriptional regulation of myelin protein gene expression. Ann N Y Acad Sci 1991, 633:178-188.
20. Cheng J.D., de Vellis J. Oligodendrocytes as glucocorticoids target cells: functional analysis of the glycerol phosphate dehydrogenase gene. J Neurosci Res 2000, 59(3):436-445.
21. Kumar S., Cole R., Chiappelli F., et al. Differential regulation of oligodendrocyte markers by glucocorticoids: post-transcriptional regulation of both proteolipid protein and myelin basic protein and transcriptional regulation of glycerol phosphate dehydrogenase. Proc Natl Acad Sci U S A 1989, 86(17):6807-6811.
22. Bellavance M.A., Rivest S. The neuroendocrine control of the innate immune system in health and brain diseases. Immunol Rev 2012, 248(1):36-55.
23. Sun Y.Y., Wang C.Y., Hsu M.F., et al. Glucocorticoid protection of oligodendrocytes against excitotoxin involving hypoxia-inducible factor-1alpha in a cell-type-specific manner. J Neurosci 2010, 30(28):9621-9630.
24. Vinukonda G., Dummula K., Malik S., et al. Effect of prenatal glucocorticoids on cerebral vasculature of the developing brain. Stroke 2010, 41(8):1766-1773.
25. Stonestreet B.S., Patlak C.S., Pettigrew K.D., et al. Ontogeny of blood-brain barrier function in ovine fetuses, lambs, and adults. Am J Physiol 1996, 271(6 Pt 2):R1594-R1601.
26. Stonestreet B.S., Petersson K.H., Sadowska G.B., et al. Antenatal steroids decrease blood-brain barrier permeability in the ovine fetus. Am J Physiol 1999, 276(2 Pt 2):R283-R289.
27. Stonestreet B.S., Sadowska G.B., McKnight A.J., et al. Exogenous and endogenous corticosteroids modulate blood-brain barrier development in the ovine fetus. Am J Physiol Regul Integr Comp Physiol 2000, 279(2):R468-R477.
28. Stonestreet B.S., Elitt C.M., Markowitz J., et al. Effects of antenatal corticosteroids on regional brain and non-neural tissue water content in the ovine fetus. J Soc Gynecol Investig 2003, 10(2):59-66.
29. Kim C.R., Sadowska G.B., Newton S.A., et al. Na+, K+-ATPase activity and subunit protein expression: ontogeny and effects of exogenous and endogenous steroids on the cerebral cortex and renal cortex of sheep. Reprod Sci 2011, 18(4):359-373.
30. Ron N.P., Kazianis J.A., Padbury J.F., et al. Ontogeny and the effects of corticosteroid pretreatment on aquaporin water channels in the ovine cerebral cortex. Reprod Fertil Dev 2005, 17(5):535-542.
31. Sysyn G.D., Petersson K.H., Patlak C.S., et al. Effects of postnatal dexamethasone on blood-brain barrier permeability and brain water content in newborn lambs. Am J Physiol Regul Integr Comp Physiol 2001, 280(2):R547-R553.
32. McGowan J.E., Sysyn G., Petersson K.H., et al. Effect of dexamethasone treatment on maturational changes in the NMDA receptor in sheep brain. J Neurosci 2000, 20(19):7424-7429.
33. Malaeb S.N., Hovanesian V., Sarasin M.D., et al. Effects of maternal antenatal glucocorticoid treatment on apoptosis in the ovine fetal cerebral cortex. J Neurosci Res 2009, 87(1):179-189.
34. Stonestreet B.S., Watkins S., Petersson K.H., et al. Effects of multiple courses of antenatal corticosteroids on regional brain and somatic tissue water content in ovine fetuses. J Soc Gynecol Investig 2004, 11(3):166-174.
35. Hai C.M., Sadowska G., Francois L., et al. Maternal dexamethasone treatment alters myosin isoform expression and contractile dynamics in fetal arteries. Am J Physiol Heart Circ Physiol 2002, 283(5):H1743-H1749.
36. Mehter N.S., Sadowska G.B., Malaeb S.N., et al. Na+, K+-ATPase activity and subunit isoform protein abundance: effects of antenatal glucocorticoids in the frontal cerebral cortex and renal cortex of ovine fetuses. Reprod Sci 2009, 16(3):294-307.
37. Sorrells S.F., Sapolsky R.M. An inflammatory review of glucocorticoid actions in the CNS. Brain Behav Immun 2007, 21(3):259-272.
38. Nadeau S., Rivest S. Glucocorticoids play a fundamental role in protecting the brain during innate immune response. J Neurosci 2003, 23(13):5536-5544.
39. Mastorakos G., Ilias I. Maternal and fetal hypothalamic-pituitary-adrenal axes during pregnancy and postpartum. Ann N Y Acad Sci 2003, 997:136-149.
40. Murphy B.E. Human fetal serum cortisol levels related to gestational age: evidence of a midgestational fall and a steep late gestational rise, independent of sex or mode of delivery. Am J Obstet Gynecol 1982, 144(3):276-282.
41. Meijer O.C., de Lange E.C., Breimer D.D., et al. Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-glycoprotein knockout mice. Endocrinology 1998, 139(4):1789-1793.
42. Wyrwoll C.S., Holmes M.C., Seckl J.R. 11beta-hydroxysteroid dehydrogenases and the brain: from zero to hero, a decade of progress. Front Neuroendocrinol 2011, 32(3):265-286.
43. Holmes M.C., Sangra M., French K.L., et al. 11beta-Hydroxysteroid dehydrogenase type 2 protects the neonatal cerebellum from deleterious effects of glucocorticoids. Neuroscience 2006, 137(3):865-873.
44. Heine V.M., Rowitch D.H. Hedgehog signaling has a protective effect in glucocorticoid-induced mouse neonatal brain injury through an 11betaHSD2-dependent mechanism. J Clin Invest 2009, 119(2):267-277.
45. Robson A.C., Leckie C.M., Seckl J.R., et al. 11 Beta-hydroxysteroid dehydrogenase type 2 in the postnatal and adult rat brain. Brain Res Mol Brain Res 1998, 61(1-2):1-10.
46. Noguchi K.K., Lau K., Smith D.J., et al. Glucocorticoid receptor stimulation and the regulation of neonatal cerebellar neural progenitor cell apoptosis. Neurobiol Dis 2011, 43(2):356-363.
47. De Kloet E.R., Vreugdenhil E., Oitzl M.S., et al. Brain corticosteroid receptor balance in health and disease. Endocr Rev 1998, 19(3):269-301.
48. Funder J.W. Glucocorticoid and mineralocorticoid receptors: biology and clinical relevance. Annu Rev Med 1997, 48:231-240.
49. Sousa N., Almeida O.F. Corticosteroids: sculptors of the hippocampal formation. Rev Neurosci 2002, 13(1):59-84.
50. Hu P., Oomen C., van Dam A.M., et al. A single-day treatment with mifepristone is sufficient to normalize chronic glucocorticoid induced suppression of hippocampal cell proliferation. PLoS One 2012, 7(9):e46224.
51. Hassan A.H., von Rosenstiel P., Patchev V.K., et al. Exacerbation of apoptosis in the dentate gyrus of the aged rat by dexamethasone and the protective role of corticosterone. Exp Neurol 1996, 140(1):43-52.
52. Sundberg M., Savola S., Hienola A., et al. Glucocorticoid hormones decrease proliferation of embryonic neural stem cells through ubiquitin-mediated degradation of cyclin D1. J Neurosci 2006, 26(20):5402-5410.
53. Mayer J.L., Klumpers L., Maslam S., et al. Brief treatment with the glucocorticoid receptor antagonist mifepristone normalises the corticosterone-induced reduction of adult hippocampal neurogenesis. J Neuroendocrinol 2006, 18(8):629-631.
54. Claessens S.E., Belanoff J.K., Kanatsou S., et al. Acute effects of neonatal dexamethasone treatment on proliferation and astrocyte immunoreactivity in hippocampus and corpus callosum: towards a rescue strategy. Brain Res 2012, 1482:1-12.
55. Tauber S.C., Schlumbohm C., Schilg L., et al. Intrauterine exposure to dexamethasone impairs proliferation but not neuronal differentiation in the dentate gyrus of newborn common marmoset monkeys. Brain Pathol 2006, 16(3):209-217.
56. Tijsseling D., Wijnberger L.D., Derks J.B., et al. Effects of antenatal glucocorticoid therapy on hippocampal histology of preterm infants. PLoS One 2012, 7(3):e33369.
57. Fukumoto K., Morita T., Mayanagi T., et al. Detrimental effects of glucocorticoids on neuronal migration during brain development. Mol Psychiatry 2009, 14(12):1119-1131.
58. Brummelte S., Lieblich S.E., Galea L.A. Gestational and postpartum corticosterone exposure to the dam affects behavioral and endocrine outcome of the offspring in a sexually-dimorphic manner. Neuropharmacology 2012, 62(1):406-418.
59. Raschke C., Schmidt S., Schwab M., et al. Effects of betamethasone treatment on central myelination in fetal sheep: an electron microscopical study. Anat Histol Embryol 2008, 37(2):95-100.
60. Antonow-Schlorke I., Helgert A., Gey C., et al. Adverse effects of antenatal glucocorticoids on cerebral myelination in sheep. Obstet Gynecol 2009, 113(1):142-151.
61. Dunlop S.A., Archer M.A., Quinlivan J.A., et al. Repeated prenatal corticosteroids delay myelination in the ovine central nervous system. J Matern Fetal Med 1997, 6(6):309-313.
62. Huang W.L., Harper C.G., Evans S.F., et al. Repeated prenatal corticosteroid administration delays myelination of the corpus callosum in fetal sheep. Int J Dev Neurosci 2001, 19(4):415-425.
63. Yu S., Patchev A.V., Wu Y., et al. Depletion of the neural precursor cell pool by glucocorticoids. Ann Neurol 2010, 67(1):21-30.
64. Ferriero D.M. Neonatal brain injury. N Engl J Med 2004, 351(19):1985-1995.
65. Miles D.K., Kernie S.G. Hypoxic-ischemic brain injury activates early hippocampal stem/progenitor cells to replace vulnerable neuroblasts. Hippocampus 2008, 18(8):793-806.
66. Elitt C.M., Sadowska G.B., Stopa E.G., et al. Effects of antenatal steroids on ischemic brain injury in near-term ovine fetuses. Early Hum Dev 2003, 73(1-2):1-15.
67. Bennet L., Davidson J.O., Koome M., et al. Glucocorticoids and preterm hypoxic-ischemic brain injury: the good and the bad. J Pregnancy 2012, 2012:751694.
68. Diamond D.M., Bennett M.C., Fleshner M., et al. Inverted-U relationship between the level of peripheral corticosterone and the magnitude of hippocampal primed burst potentiation. Hippocampus 1992, 2(4):421-430.
69. McEwen B.S. Central effects of stress hormones in health and disease: understanding the protective and damaging effects of stress and stress mediators. Eur J Pharmacol 2008, 583(2-3):174-185.
70. Roberts D., Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2006, (3). CD004454.
71. Ment L.R., Oh W., Ehrenkranz R.A., et al. Antenatal steroids, delivery mode, and intraventricular hemorrhage in preterm infants. Am J Obstet Gynecol 1995, 172(3):795-800.
72. Feldman D.M., Carbone J., Belden L., et al. Betamethasone vs dexamethasone for the prevention of morbidity in very-low-birthweight neonates. Am J Obstet Gynecol 2007, 197(3):284.e1-284.e4.
73. Crowther C.A., Haslam R.R., Hiller J.E., et al. Neonatal respiratory distress syndrome after repeat exposure to antenatal corticosteroids: a randomised controlled trial. Lancet 2006, 367(9526):1913-1919.
74. Wapner R.J., Sorokin Y., Mele L., et al. Long-term outcomes after repeat doses of antenatal corticosteroids. N Engl J Med 2007, 357(12):1190-1198.
75. Crowther C.A., Doyle L.W., Haslam R.R., et al. Outcomes at 2 years of age after repeat doses of antenatal corticosteroids. N Engl J Med 2007, 357(12):1179-1189.
76. Spinillo A., Viazzo F., Colleoni R., et al. Two-year infant neurodevelopmental outcome after single or multiple antenatal courses of corticosteroids to prevent complications of prematurity. Am J Obstet Gynecol 2004, 191(1):217-224.
77. Huysman M.W., Hokken-Koelega A.C., De Ridder M.A., et al. Adrenal function in sick very preterm infants. Pediatr Res 2000, 48(5):629-633.
78. Scott S.M., Watterberg K.L. Effect of gestational age, postnatal age, and illness on plasma cortisol concentrations in premature infants. Pediatr Res 1995, 37(1):112-116.
79. Ng P.C., Lee C.H., Lam C.W., et al. Transient adrenocortical insufficiency of prematurity and systemic hypotension in very low birthweight infants. Arch Dis Child Fetal Neonatal Ed 2004, 89(2):F119-F126.
80. Watterberg K.L., Gerdes J.S., Cole C.H., et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics 2004, 114(6):1649-1657.
81. Watterberg K. Evidence-based neonatal pharmacotherapy: postnatal corticosteroids. Clin Perinatol 2012, 39(1):47-59.
82. Inder T.E., Benders M. Postnatal steroids in the preterm infant-the good, the ugly, and the unknown. J Pediatr 2013, 162(4):667-670.
83. Roberts R.S. Early closure of the Watterberg trial. Pediatrics 2004, 114(6):1670-1671.
84. Stark A.R., Carlo W.A., Tyson J.E., et al. Adverse effects of early dexamethasone in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 2001, 344(2):95-101.
85. Doyle L.W., Ehrenkranz R.A., Halliday H.L. Dexamethasone treatment in the first week of life for preventing bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology 2010, 98(3):217-224.
86. Doyle L.W., Ehrenkranz R.A., Halliday H.L. Postnatal hydrocortisone for preventing or treating bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology 2010, 98(2):111-117.
87. Halliday H.L., Ehrenkranz R.A., Doyle L.W. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003, (1). CD001144.
88. Halliday H.L., Ehrenkranz R.A., Doyle L.W. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003, (1). CD001145.
89. Onland W., Offringa M., De Jaegere A.P., et al. Finding the optimal postnatal dexamethasone regimen for preterm infants at risk of bronchopulmonary dysplasia: a systematic review of placebo-controlled trials. Pediatrics 2009, 123(1):367-377.
90. Wilson-Costello D., Walsh M.C., Langer J.C., et al. Impact of postnatal corticosteroid use on neurodevelopment at 18 to 22 months' adjusted age: effects of dose, timing, and risk of bronchopulmonary dysplasia in extremely low birth weight infants. Pediatrics 2009, 123(3):e430-e437.
91. Cummings J.J., D'Eugenio D.B., Gross S.J. A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. N Engl J Med 1989, 320(23):1505-1510.
92. O'Shea T.M., Kothadia J.M., Klinepeter K.L., et al. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics 1999, 104(1 Pt 1):15-21.
93. Mizobuchi M., Iwatani S., Sakai H., et al. Effect of hydrocortisone therapy on severe leaky lung syndrome in ventilated preterm infants. Pediatr Int 2012, 54(5):639-645.
94. Ben Said M., Hays S., Loys C.M., et al. Postnatal steroids in extremely low birth weight infants: betamethasone or hydrocortisoneα. Acta Paediatr 2013, 102(7):689-694.
95. Kersbergen K.J., de Vries L.S., van Kooij B.J., et al. Hydrocortisone treatment for bronchopulmonary dysplasia and brain volumes in preterm infants. J Pediatr 2013, 163:666-671.e1.
96. Parikh N.A., Kennedy K.A., Lasky R.E., et al. Pilot randomized trial of hydrocortisone in ventilator-dependent extremely preterm infants: effects on regional brain volumes. J Pediatr 2013, 162(4):685-690.e1.
97. Benders M.J., Groenendaal F., van Bel F., et al. Brain development of the preterm neonate after neonatal hydrocortisone treatment for chronic lung disease. Pediatr Res 2009, 66(5):555-559.
98. Van Marter L.J., Kuban K.C., Allred E., et al. Does bronchopulmonary dysplasia contribute to the occurrence of cerebral palsy among infants born before 28 weeks of gestationα. Arch Dis Child Fetal Neonatal Ed 2011, 96(1):F20-F29.
99. Doyle L.W., Halliday H.L., Ehrenkranz R.A., et al. Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease. Pediatrics 2005, 115(3):655-661.
100. Laughon M., Allred E.N., Bose C., et al. Patterns of respiratory disease during the first 2 postnatal weeks in extremely premature infants. Pediatrics 2009, 123(4):1124-1131.
101. Banks B.A., Stouffer N., Cnaan A., et al. Association of plasma cortisol and chronic lung disease in preterm infants. Pediatrics 2001, 107(3):494-498.
102. Watterberg K.L., Scott S.M. Evidence of early adrenal insufficiency in babies who develop bronchopulmonary dysplasia. Pediatrics 1995, 95(1):120-125.
103. Watterberg K.L., Scott S.M., Backstrom C., et al. Links between early adrenal function and respiratory outcome in preterm infants: airway inflammation and patent ductus arteriosus. Pediatrics 2000, 105(2):320-324.
104. Peltoniemi O., Kari M.A., Heinonen K., et al. Pretreatment cortisol values may predict responses to hydrocortisone administration for the prevention of bronchopulmonary dysplasia in high-risk infants. J Pediatr 2005, 146(5):632-637.
105. Onland W., Offringa M., Cools F., et al. Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants (the SToP-BPD study); a multicenter randomized placebo controlled trial. BMC Pediatr 2011, 11:102.
106. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). Hydrocortisone for BPD. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited 2013]. Available from. NLM Identifier: NCT01353313. Accessed September 26, 2013. http://www.clinicaltrials.gov/ct2/show/NCT01353313.